By Ahmed Aboulenein, Julie Steenhuysen and Maggie FickWASHINGTON (Reuters) -The Trump administration's mass firings at the U.S. Food and Drug Administration have removed employees critical to reviewing new medicines,

Combined with earlier buyouts and retirements, the Health and Human Services Department will be left with 62,000 employees, down from around 82,000. Agencies face an April 14 deadline to present details of which employees will be cut in order to comply with Mr. Trump’s government-shrinking objective.

Agency heads responded to the executive order, and, in conjunction with efforts by the Department of Government Efficiency (DOGE), more than 50,000 federal workers have been laid

Wall Street nosedived for a second straight day on Friday, with the Nasdaq Composite confirming a bear market and the Dow Jones Industrial Average entering a correction, as an escalating global trade war spurred the biggest losses since the pandemic.

During a webinar hosted by NAMSA, experts reflected on what US health agency job cuts could mean for device approvals and innovation.

Stocks tumbled again Friday as China imposed retaliatory tariffs. Tariffs will probably drive higher inflation, the Federal Reserve projects. Economists are criticizing Trump’s tariff calculations. The Social Security Administration is planning more layoffs next week.

The White House released a statement on Friday, noting March's job report shows the private sector is "roaring back" under the Trump administration.

Automaker Stellantis NV (STLA) announced plans to lay off 900 workers across five of its facilities in the U.S. and temporarily suspend operations at assembly plants in Mexico and Canada due to uncertainty about the Trump administration’s sweeping reciprocal tariffs on Thursday.

Mass firings took place today at federal health agencies amid the Trump administration's slashing of federal jobs.